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Introduction 
For the first time, the 2009 Pharmacology and Molecular 
Mechanisms (PAMM) winter meeting was organized in 
connection with the EGAM (EORTC Groups Annual Meeting) in 
Brussels. Furthermore, the PAMM participated in an additional 
plenary session together with the PathoBiology Group and the 
functional imaging group during the EGAM itself, in which the 
Laboratory Research Division summarized their expertise in 
translational research and gave an overview of what it can offer 
to the Disease Oriented Groups. The emphasis of the joint 
meeting was on novel concepts in cancer treatment and on new 
approaches to monitor therapy and implement personalized 
strategies. 
Three main subtopics could be possibly canvassed out of whole 
meeting, namely, (a) apoptosis and signalling, (b) cancer stem 
cells, (c) cancer genome and epigenome profiling. 
(a) Targeting apoptosis 
Most anti-cancer therapies act by triggering apoptosis in cancer 
cells. Therefore, defects in apoptosis programmes, for example 
aberrant expression of anti-apoptotic proteins, may render 
cancer cells resistant to treatment. Indeed, deregulation of 
apoptosis is one of the hallmarks of malignant cells, allowing 
their survival in the context of an altered genome and in harsh 
tumour environments with low levels of oxygen and nutrients. 
Understanding of the molecular mechanisms underlying 
apoptosis suppression in cancer has provided rationales for the 
design of apoptosis targeted therapies. 
One strategy was illustrated by Simone Fulda (University 
Children's Hospital, Ulm, Germany) and involves the targeting of 
inhibitors of apoptosis proteins (IAPs), which are expressed at 
high levels in many human cancers and block apoptosis by 
inhibiting effector caspases. Fulda showed how targeting XIAP 
(one member of the IAP family) by RNA interference-mediated 
knockdown or small molecule inhibitors cooperates with TRAIL 
(tumour-necrosis-related apoptosis-induced ligand) to suppress 
growth in both in vitro and in vivo models of pancreatic cancer 
and in childhood acute leukaemia cells [14,25]. In this context, 
IAP inhibitors appear to be promising therapeutic tools, and they 
have recently entered early clinical trials in the form of small 
peptides. 
Nadia Zaffaroni (Fondazione IRCCS Istituto Nazionale dei 
tumouri, Milan, Italy) showed promising in vitro and in vivo
data on ‘survivin’ inhibition, another member of the IAP family of 
apoptosis inhibitors. Survivin is a bifunctional protein that in 
addition to acting as a suppressor of programmed cell death 
also plays a central role in cell division. Owing to its massive up-
regulation in human tumours and its involvement in cancer 
progression and treatment resistance, survivin is currently 
undergoing extensive investigation as a promising target for 
new anti-cancer interventions. Zaffaroni showed how the down-
regulation of this protein, accomplished by means of various 
strategies (including the use of antisense oligonucleotides, 
small interfering RNAs, ribozymes, dominant negative mutants 
and small molecules antagonists) reduced tumour growth 
potential, increased the apoptotic rate and sensitized tumour 
cells to chemo- and radiotherapeutic agents in different tumour 
pre-clinical models [18]. The first survivin inhibitors have already 
reached the clinic: the YM155 molecule is currently in phase 1–
2 studies [22]. However, due to its central role in promoting cell 
division in normal cells, the effects of survivin disruption on 
normal tissues and the related possible toxicities must be 
further investigated. 
Frank A Kruyt (University Medical Center Groningen, the 
Netherlands) presented his work on bortezomib, an interesting 
compound that can reversibly inhibit the proteasome and induce 
mitochondrial-dependent apoptosis [26]. Kruyt argued that 
bortezomib may be an interesting targeting moiety for non-
small-cell lung cancer (NSCLC), a disease with poor survival 
rates, which represents 80–85% of lung cancer cases. The 
combined administration of TRAIL/bortezomib proved highly 
effective in inducing mitochondrial-dependent apoptosis in both 
in vitro and in vivo models of NSCLC. Mechanistic studies are 
ongoing to better understand the favourable drug interactions. 
In the clinic, recombinant TRAIL preparations and agonistic 
antibodies are under examination and combination strategies 
are in progress, including mapatumumab (TRAIL-R1/DR4 mAb) 
and bortezomib in multiple myeloma [6–8]. 
(b) Targeting cancer stem cells 
The idea of targeting tumour stem cells for cancer treatment first 
became prominent in the 1970s with the introduction of the 
‘human tumour stem cell assay’ by Hamburger and Salmon 
[15]. Twenty years after that first report, interest in the tumour 
stem cell has re-emerged out of the increasing understanding of 
normal human stem cell biology and work documenting the 
existence of human leukaemic stem cells bearing characteristic 
cell surface markers [1]. Interest in targeting tumour stem cells





















has been based on the notion that these cells resist currently 
available therapies and contribute to the regrowth of tumours 
following chemotherapy. Robert H Shoemaker (Division of 
Cancer Treatment and Diagnosis, National Cancer Institute, 
USA) presented data on the characterization of the in vitro drug 
sensitivity phenotype of isolated tumour stem cells from glioma 
samples and established tumour cell lines. A high degree of 
heterogeneity in the expression of several markers tested and 
the existence of sub-populations of tumour stem cells 
expressing different sets of markers were pointed out, together 
with a high heterogeneity in the resistance to more than 50 
drugs tested [20]. Some unresolved issues in the quantitation of 
the fraction of tumour stem cells in patient samples were also 
highlighted, namely the need to standardize the experiments, 
and the results, according to the strain of immunodeficient mice 
used, the site and mode of implantation. 
Louis Vermeulen (Academic Medical Center, Amsterdam, the 
Netherlands) focused on colon cancer stem cells. Colon 
carcinomas often consist of a range of cells expressing various 
differentiation markers. In analogy to normal colon crypts, 
goblet-like, enterocyte-like or enteroendocrine-like differentiation 
patterns are observed. Vermeulen argued in favour of this set of 
separate differentiation routes emanating from a single-colon 
cancer stem cells. To support his claim, he presented data 
showing how a primary tumour can be regenerated in a mouse 
using single-cell cloned cancer stem cells (CSCs), either after in 
vitro culture or directly from the human tumour specimen [24]. In 
addition, Vermeulen showed recent work, revealing that 
regulation of the Wnt signalling cascade in colorectal cancer 
cells harbouring APC mutations occurs and is related to the 
CSC phenotype both in vitro and in vivo. Currently, his group is 
investigating the molecules involved in the regulation of the 
aberrant Wnt cascade, which may serve as a promising future 
therapeutic target. 
The relationship between cancer stem cells and circulating 
cancer cells, and their potential for metastasis, was investigated 
in the talks given by Sieuwerts and Fodstad. 
Anieta M Sieuwerts (Josephine Nefkens Institute, Erasmus MC, 
Rotterdam, the Netherlands) focused on the CellSearch
TM 
method to identify circulating tumour cells (CTCs), and on its 
pitfall in detecting the aggressive subtype of breast CTCs 
responsible for metastasis and relapse, namely 'normal-like 
breast tumour cells'. Indeed, the CellSearch
TM isolation method, 
which uses epithelial cell adhesion molecules such as EpCAM 
to detect such tumour cells, is not able to recognize normal-like 
breast cancer cells, which, in general, have aggressive features 
and are negative for the expression of EpCAM. Therefore, new
tests that identify antibodies, which specifically recognize 
normal-like breast tumour cells must be pursued. Sieuwerts 
proposed useful criteria for the selection of addition cell surface 
antigens [21]. Furthermore, epithelial mesenchymal transition 
(EMT) is a process that has been linked to the ability of breast 
cancer stem cells to give rise to metastasis [19,17]. Sieuwerts 
pointed out how the normal-like breast cancer subtype is the 
main subtype with EMT characteristics. Therefore, these cells 
are important targets for the development of individualized 
therapies. According to Sieuwerts, these cells may represent a 
subset of the cancer stem cells present in the original tumour 
lesion. 
The relationship between CSCs and CTCs has been 
investigated also by Øystein Fodstad (Institute for Cancer 
Research, Norwegian Radium Hospital, Oslo, Norway), who 
focused on methods for detecting disseminated tumour cells. 
The presence of micro-metastatic tumour cells in peripheral 
blood and bone marrow has been shown to correlate with poor 
outcome. The technologies used to detect micro-metastatic 
cells have several limitations in terms of specificity and 
sensitivity and of false positives and false negatives, as the 
huge discrepancy in the fraction of breast cancer stem cells in 
published results demonstrates. In general, methods must cope 
with two questions. First, how do we know we are actually 
detecting tumour cells? As for the second, Fodstad raised a 
point discussed also by Sieuwerts: do micro-metastatic cells 
express stem cell markers and what is their relationship with 
cancer stem cells? Fodstad illustrated the work of his group on 
the development of an immunomagnetic method for selective 
isolation of micro-metastatic cells in body fluids and solid 
tissues, simultaneously examining the expression of cell 
membrane markers by the use of non-magnetic fluorescent 
micro-particles coated with relevant antibodies. These live, 
bead-bound cells are then collected and used for RT-PCR and 
array comparative genomic hybridization (aCGH) studies and 
for the comparison of cells from different compartments [11]. 
(c) Profiling the cancer genome and epigenome 
A novel approach exploiting this last tool (aCGH studies) for 
diagnosis and patient treatment was illustrated by Bauke Ylstra 
(VU University Medical Center, Amsterdam, the Netherlands). 
This method is based on the assumption that patient-tailored 
medicine requires matching of the most effective therapy with 
the molecular characteristics of a cancer. Therefore, the 
molecular heterogeneity of the individual patient's tumour needs 
to be recognized. Chromosomal copy number aberrations 
(CNAs) offer opportunities to stratify patient samples for therapy





















[5] and aCGH is the high-resolution laboratory technique of 
choice to detect such CNAs with high resolution and on a 
genome wide scale [28]. Unsupervised clustering of 
chromosomal copy number profiles allows sub-classes of 
mammary tumours, which are tightly linked to survival in 
independent datasets to be distinguished [2,3]. In addition, 
Ylstra pointed out how CNAs could function as markers to 
predictor response to chemotherapy in advanced colorectal 
cancer. aCGH can also be used for identification of novel drug 
targets targeting small, focal aberrations less than 1 Mb long. In 
total, Ylstra showed how CNAs can serve as a marker for better 
cancer classification, prognosis, and outcome prediction. He 
also argued in favour of aCGH as a better diagnostic and 
prognostic tool compared to expression profiling, since DNA is a 
more stable molecule than RNA. The value of aCGH clustering 
can however be increased, Ylstra contended, by coupling CNAs 
profiles with RNA profiles. 
John Martens (Josephine Nefkens Institute, Rotterdam, the 
Netherlands) focused instead on the other side of the ‘genomic 
tool-coin’ for the molecular understanding of cancer and for 
guiding personalized therapy. He argued in favour of micro-
RNAs as prognostic and predictive tumour markers, in particular 
in breast cancer [13]. Micro-RNAs (miRNAs) are small 
ribonucleotides (16–29 nt) that use the endogenous RNA 
interference pathway to modulate gene expression in a tissue 
and developmental stage-dependent manner. Martens and co-
authors presented an innovative study in breast cancer aimed at 
assessing which miRNAs are associated with more aggressive 
tumour phenotype and poor prognosis or clinical benefit from 
endocrine therapy. An analysis of 249 miRNAs in 38 primary 
breast cancers identified four miRNAs correlated with poor 
prognosis and three others with a favourable response to 
endocrine therapy with tamoxifen. Then, using the available 
gene expression data from these cohorts of patients Martens 
and co-authors determined which biological pathways were co-
expressed with the identified prognostic or predictive 
microRNAs. To conclude, Martens stressed how global miRNA 
signatures can lead to the identification of miRNAs predictive of 
prognosis, response and to novel targeted therapies [10]. 
The most original talk was undoubtedly given by Terry Jones 
(Manchester, England), the only speaker who focused on the 
innovative role of molecular imaging in clinical trials. In 
particular, Jones and co-authors talked about positron emission 
tomography (PET) as a tool for early clinical trials and for filling 
in the gap between the laboratory and the clinic [27]. Indeed, as 
a means for supporting drug development, PET offers 
measurements of regional tissue pharmacokinetics and
pharmacodynamics and provides quantitative ‘proof-of-concept’ 
information on mechanisms and efficacies of action. According 
to Jones, the future of cancer clinical trials is in imaging-based 
microdose studies, such as phase 0 studies, which would offer 
opportunities for rapid first into humans trials and avoid the 
need of massive toxicology testing [9]. However, the field of 
molecular imaging studies is still underdeveloped, and Jones 
pointed out the challenges that are slowing down the potential 
use of PET to support phase 1 oncology studies, such as the 
need to discover specific-imaging biomarkers for tumour tissue. 
 
Conclusion 
The first PAMM-EORTC joint meeting pointed out some 
common challenges in the direction towards targeted, 
personalized therapy for cancer. One of these promising routes 
is through targeting cancer stem cells. 
The cancer stem cell hypothesis proposes that cancer stem 
cells are a minority population of self-renewing cancer cells that 
fuel tumour growth and remain in patients after conventional 
therapy has been completed. The model predicts that effective 
tumour eradication will require obtaining agents that can target 
cancer stem cells whilst sparing normal stem cells. Vermeulen 
hinted at the problem of the integration of this model within the 
model of carcinogenesis postulated by Nowell and Vogelstein, 
which describes the formation of a tumour by the sequential 
accumulation of mutations in oncogenes and tumour suppressor 
genes [23]. Vermeulen also dwelled on the problem of the 
definition of these cells, since and accurate and common 
definition is critical to enable researchers working in the same or 
different systems to compare cells exhibiting a common set of 
properties. The term 'cancer stem cell' has led to some 
confusion, and some scholars prefer to use the term 'tumour 
initiating cell' [16]. 
According to Vermeulen, the consensus definition of a cancer 
stem cell that was reached the AACR 2006 Workshop (‘a cell 
within a tumour that possess the capacity to self-renew and to 
cause the heterogeneous lineages of cancer cells that comprise 
the tumour’) is a satisfactory solution, even though it is only an 
operational definition [4]. 
Shoemaker pointed out some of the challenges that may hinder 
the translation of the cancer stem cell promise to the clinic. 
Indeed, the moving target nature of cancer stem cells may 
present a serious obstacle for drug development. To achieve 
effective implementation of new therapies, physicians will





















require methods of determining the type (or types) of cancer 
stem cells present in a given patient's tumour. It is therefore of 
pivotal importance that agents directed against cancer stem 
cells discriminate between tumour stem cells and normal stem 
cells. 
The problem of the discrimination of the normal from the 
pathological compartment (and the related point of cancer drug 
toxicity) is not limited to compounds targeting cancer stem cells; 
Zaffaroni also highlighted this issue describing what needs to be 
done in targeting apoptosis, such as when inhibiting survivin. 
The still incomplete clarification of the relationship between 
cancer stem cells and circulating tumour cells is at present 
another hurdle for the translation of the model to the clinic. Both 
the presentations by Sieuwerts and Fodstad elucidated different 
aspects of this problem, which surely has significant therapeutic 
implications. Indeed, some questions still remain open: Are 
circulating tumour cells a subset of cancer stem cells? What is 
the role of the epithelial mesenchymal transition in the 
acquisition of an aggressive phenotype and of the metastatic 
potential? Are micro-metastatic cells the same thing as 
circulating tumour cells? 
Genomic tools for cancer profiling, such as the ones illustrated 
by Ylstra and Martens, might be the solution for this kind of
question, as they may help identifying DNA and RNA signatures 
predictive of clinical response and outcome. The ultimate goal is 
the stratification of patients according to their tumour signatures 
and the development of a more effective personalized 
treatment. To achieve these results, advancement in molecular 
imaging tools, such as PET-based clinical trials, need to be 
boosted, as underlined by Terry Jones. The potentiality of the 
molecular imaging studies is still not fully developed, due to the 
lack of suitable biomarkers and to the sub-optimal receptivity of 
the field to the existing guidelines on microdose studies, one of 
the main applications of the new phase 0 trials [12]. 
To conclude, several roads towards the shared goal of targeted 
and personalized cancer therapy have been paved. These go 
through the modulation of apoptosis pathways, cancer stem 
cells and micro-metastic cells, chromosomal aberrations and 
tumour-upregulated miRNAs and the stratification of patients 
according to their tumour DNA and RNA profiles. Different 
routes need not be necessarily mutually exclusive, since they 
could greatly profit by favourable interactions between diverse 
expertises. One example of this 'virtuous circle' was 
demonstrated by the fruitful exchanges of ideas between 
Laboratory Research Division and Disease Oriented Groups 
that took place this year in Brussels. Let us hope it is not the 
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